FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282483> ?p ?o ?g. }

• W4379282483 endingPage "7068" @default.
• W4379282483 startingPage "7068" @default.
• W4379282483 abstract "7068 Background: In patients with myelofibrosis (MF), JAK inhibitor therapy can improve both splenomegaly and disease symptoms. Unfortunately, dosing – and thus efficacy – of available current JAK1/2 inhibitors is frequently limited in patients with cytopenic MF due to drug-induced exacerbation of cytopenias. Pacritinib is a novel JAK1-sparing inhibitor of JAK2/IRAK1/ACVR1 that has been studied at full dose in patients with MF regardless of cytopenias. Here, we present data on spleen and symptom benefit in pacritinib-treated patients across the cytopenic spectrum, stratified by both baseline platelet (PLT) count and hemoglobin (HB) level. Methods: Evaluable patients treated with pacritinib in the PERSIST-1 and PERSIST-2 studies were analyzed, stratified by baseline PLT (<100, ≥100x10 9 /L) and HB (<8, 8 to <10, ≥10 g/dL). Groups were analyzed for depth of spleen volume response (SVR), modified total symptom score (TSS) response, patient global impression of change (PGIC), and dose intensity. Results: Of 276 patients evaluable for spleen response, median age was 67 years, 51.5% had grade 3 fibrosis, 70% had primary MF, and 16% had prior JAK2 inhibitor exposure. Median dose intensity was >99.7% for the duration of the study across PLT and HB subgroups. Overall, 80% of patients had ≥10% SVR (SVR-10), 75.5% had TSS-10, and 78% reported that their symptoms were improved at week 24. Week 24 spleen reduction occurred consistently across PLT and HB strata, with 84-93% and 86-90% of patients respectively (Table). SVR-35 occurred in 23-25% of patients across PLT strata and in 21-28% of patients across HB strata. Symptom response was also consistent across strata, though TSS-50 occurred at highest rates (62.5%) in patients with HB <8 g/dL. There was no diminution in symptom burden reduction in patients with thrombocytopenia (Table). Across all subgroups, at least three-quarters of patients reported symptoms were “improved” at week 24. Conclusions: Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of blood counts. This consistent effect may be related to pacritinib’s unique kinome profile and its ability to be delivered at full dose in patients regardless of cytopenias. Clinical trial information: NCT01773187 , NCT02055781 . [Table: see text]" @default.
• W4379282483 created "2023-06-05" @default.
• W4379282483 creator A5013173470 @default.
• W4379282483 creator A5013310470 @default.
• W4379282483 creator A5017537622 @default.
• W4379282483 creator A5037079497 @default.
• W4379282483 creator A5038004259 @default.
• W4379282483 creator A5053069175 @default.
• W4379282483 creator A5057876119 @default.
• W4379282483 creator A5067214379 @default.
• W4379282483 creator A5070193149 @default.
• W4379282483 creator A5074629157 @default.
• W4379282483 creator A5087100088 @default.
• W4379282483 date "2023-06-01" @default.
• W4379282483 modified "2023-10-14" @default.
• W4379282483 title "Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias." @default.
• W4379282483 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7068" @default.
• W4379282483 hasPublicationYear "2023" @default.
• W4379282483 type Work @default.
• W4379282483 citedByCount "0" @default.
• W4379282483 crossrefType "journal-article" @default.
• W4379282483 hasAuthorship W4379282483A5013173470 @default.
• W4379282483 hasAuthorship W4379282483A5013310470 @default.
• W4379282483 hasAuthorship W4379282483A5017537622 @default.
• W4379282483 hasAuthorship W4379282483A5037079497 @default.
• W4379282483 hasAuthorship W4379282483A5038004259 @default.
• W4379282483 hasAuthorship W4379282483A5053069175 @default.
• W4379282483 hasAuthorship W4379282483A5057876119 @default.
• W4379282483 hasAuthorship W4379282483A5067214379 @default.
• W4379282483 hasAuthorship W4379282483A5070193149 @default.
• W4379282483 hasAuthorship W4379282483A5074629157 @default.
• W4379282483 hasAuthorship W4379282483A5087100088 @default.
• W4379282483 hasConcept C126322002 @default.
• W4379282483 hasConcept C2776112149 @default.
• W4379282483 hasConcept C2777014857 @default.
• W4379282483 hasConcept C2780007613 @default.
• W4379282483 hasConcept C2780076729 @default.
• W4379282483 hasConcept C2780931953 @default.
• W4379282483 hasConcept C71924100 @default.
• W4379282483 hasConcept C90924648 @default.
• W4379282483 hasConceptScore W4379282483C126322002 @default.
• W4379282483 hasConceptScore W4379282483C2776112149 @default.
• W4379282483 hasConceptScore W4379282483C2777014857 @default.
• W4379282483 hasConceptScore W4379282483C2780007613 @default.
• W4379282483 hasConceptScore W4379282483C2780076729 @default.
• W4379282483 hasConceptScore W4379282483C2780931953 @default.
• W4379282483 hasConceptScore W4379282483C71924100 @default.
• W4379282483 hasConceptScore W4379282483C90924648 @default.
• W4379282483 hasFunder F4320317479 @default.
• W4379282483 hasIssue "16_suppl" @default.
• W4379282483 hasLocation W43792824831 @default.
• W4379282483 hasOpenAccess W4379282483 @default.
• W4379282483 hasPrimaryLocation W43792824831 @default.
• W4379282483 hasRelatedWork W1880500951 @default.
• W4379282483 hasRelatedWork W1883475886 @default.
• W4379282483 hasRelatedWork W2012828222 @default.
• W4379282483 hasRelatedWork W2115351357 @default.
• W4379282483 hasRelatedWork W2797422510 @default.
• W4379282483 hasRelatedWork W2903749170 @default.
• W4379282483 hasRelatedWork W2939368495 @default.
• W4379282483 hasRelatedWork W2950567676 @default.
• W4379282483 hasRelatedWork W3081443961 @default.
• W4379282483 hasRelatedWork W4296533651 @default.
• W4379282483 hasVolume "41" @default.
• W4379282483 isParatext "false" @default.
• W4379282483 isRetracted "false" @default.
• W4379282483 workType "article" @default.